Myeloma 2022

25–27 March 2022 | Scottsdale, AZ

Myeloma 2022

25–27 March 2022 | Scottsdale, AZ

VJHemOnc was pleased to be the official media partner for Myeloma 2022, the 15th workshop exploring myeloma biology and innovation. The workshop featured a global expert faculty discussing the latest updates in multiple myeloma. This year’s key topics included the clinical management of myeloma, defining the molecular basis of myeloma in the development of novel targets, immune-based therapies, and measurable residual disease (MRD).

Session 1: Genomics & High-Risk Disease
Faith  Davies
Defining and Standardizing the Approach to High-Risk Disease
Faith Davies NYU Langone Health, New York City, NY, United States
Leif  Bergsagel
Aetiologic Translocations and the Pathogenesis of MM
Leif Bergsagel Mayo Clinic, Phoenix, AZ, United States
Gareth Morgan
Whole Genomes, Mutographs and Diversity
Gareth Morgan NYU Langone Health, New York City, NY, United States
Leo Rasche
Evolutionary Pathways to End-Stage MM
Leo Rasche Würzburg University Hospital , Würzburg, Germany
Jonathan  Keats
Genomic Basis of MM Subtypes from the MMRF CoMMpass Studies
Jonathan Keats TGen, Phoenix, AZ, United States
Presentation coming soon.
Francesco Maura
Lesson from the Sequencing Analysis of the Vk*MYC Mouse Model
Francesco Maura Sylvester Comprehensive Cancer Center, Miami, FL, United States
Marta  Chesi
Using the Vk*MYC Model to Model Progression and Treatment
Marta Chesi Mayo Clinic, Phoenix, AZ, United States

Session 2: Myeloma at the Single-Cell Level
Irene Ghobrial
Myeloma at the Single-Cell Level
Irene Ghobrial Dana-Farber Cancer Institute, Boston, MA, United States
Yael Cohen
Drug Resistance from a Single-Cell Perspective
Yael Cohen Sourasky Medical Center, Tel-Aviv, Israel
Rodger Tiedemann
Single-Cell Analysis and Drug Resistance
Rodger Tiedemann Princess Margaret Cancer Center, Toronto, Canada
Niels Weinhold
The Microenvironment and Progression
Niels Weinhold Heidelberg University, Heidelberg, Germany
Presentation coming soon.
Eileen Boyle
Predicting Sustained MRD Negativity in Patients Treated with D-KRd
Eileen Boyle NYU Langone Health, New York City, NY, United States
Noopur Raje
Adipocytes and the Pathogenesis of Myeloma
Noopur Raje Massachusetts General Hospital, Boston, MA, United States
Ivan Borrello
Modulating Remission in the Immune Microenvironment
Ivan Borrello Johns Hopkins University, Baltimore, MD, United States

Session 3: Novel Targets 1
Jesús San Miguel
Future of Myeloma Therapy
Jesús San Miguel University of Navarra, Pamplona, Spain
Kenneth Anderson
Exploiting Immunogenic Cell Death
Kenneth Anderson Dana-Farber Cancer Institute, Boston, MA, United States
Nizar Bahlis
Exploiting IMiD and CELMoD Molecules
Nizar Bahlis Arnie Charbonneau Cancer Institute, Calgary, Canada
Sagar Lonial
Iberdomide in Heavily Refractory Myeloma
Sagar Lonial Emory Winship Cancer Institute, Atlanta, GA, United States
Suzanne  Lentzsch
Antibody Treatment for Amyloid
Suzanne Lentzsch Columbia University Medical Center, New York, NY, United States
Hearn Jay Cho
Personalized Therapy and Basket Trials
Hearn Jay Cho Icahn School of Medicine at Mount Sinai Hospital, New York City, NY, United States

Session 4: MRD-Directed Therapy
Rafael Fonseca
MRD-Directed Therapy
Rafael Fonseca Mayo Clinic, Phoenix, AZ, United States
Pieter  Sonneveld
Developing Curative Strategies for Younger Patients
Pieter Sonneveld Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands
Bruno Paiva
Response-Adapted Therapeutic Strategies Based on Flow MRD
Bruno Paiva University of Navarra, Pamplona, Spain
Angela  Dispenzieri
Mass Spec Approaches for MRD
Angela Dispenzieri Mayo Clinic, Rochester, MN, United States
Charlotte Pawlyn
MRD in the Latest MRC Clinical Trials
Charlotte Pawlyn The Institute of Cancer Research, London, United Kingdom
Presentation coming soon.
Session 5: Novel Targets 2
Shaji  Kumar
PROTAC Therapy for Difficult to Manipulate Targets
Shaji Kumar Mayo Clinic, Rochester, MN, United States
Lawrence  Boise
Modulating Apoptosis with MCL1 and BCL2 Inhibition
Lawrence Boise Emory Winship Cancer Institute, Atlanta, GA, United States
Presentation coming soon.
Keith  Stewart
PIKfyve Inhibitors
Keith Stewart Princess Margaret Cancer Centre, Ontario, Canada
Robert  Orlowski
Targeting RAS
Robert Orlowski MD Anderson Cancer Center, Houston, TX, United States
Presentation coming soon.
Paola Neri
Emerging Novel Immune Targets
Paola Neri University of Calgary, Alberta, Canada

Session 6: T-Cell Engagers & the Future
Hermann Einsele
T-Cell Engaging Therapy Challenges and Opportunities
Hermann Einsele Würzburg University Hospital, Würzburg, Germany
Yi  Lin
Idecabtagene Vicleucel Current Status and Future Prospects
Yi Lin Mayo Clinic, Rochester, MN, United States
Nina  Shah
Bispecifics for Multiple Myeloma
Nina Shah University of California, San Francisco, CA, United States
Thomas  Martin
Ciltacabtagene Autoleucel Current Status and Future Prospects
Thomas Martin University of California, San Francisco, CA, United States
Eric Smith
GPRC5D-Directed Bispecifics and CAR-T Therapies
Eric Smith Dana-Farber Cancer Institute, Boston, MA, United States
Adam Cohen
Targeting FcRH5 as a Strategy in MM
Adam Cohen Abramson Cancer Center, Philadelphia, PA, United States

Meeting Supporters:


Visit the Myeloma Channel for the latest updates from leading experts

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter